Stock Track | Stevanato Group Soars 14.92% in Pre-market on Strong Q4 Earnings Beat and Robust 2026 Guidance

Stock Track

Mar 04

Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.

The pharmaceutical services company reported quarterly adjusted earnings of €0.18 per share, exceeding analyst estimates of €0.17. Revenue for the quarter rose to €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by a 31% jump in revenue from high-value solutions, which reached a record €171.4 million and represented 49% of total Q4 revenue.

For fiscal year 2026, Stevanato Group provided guidance that includes revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1139133359"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139133359\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139133359?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139133359","market":"us","top_or_hot":-1,"title":"Stock Track | Stevanato Group Soars 14.92% in Pre-market on Strong Q4 Earnings Beat and Robust 2026 Guidance","media":"Stock Track","content":"<p>Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The pharmaceutical services company reported quarterly adjusted earnings of €0.18 per share, exceeding analyst estimates of €0.17. Revenue for the quarter rose to €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by a 31% jump in revenue from high-value solutions, which reached a record €171.4 million and represented 49% of total Q4 revenue.</p><p>For fiscal year 2026, Stevanato Group provided guidance that includes revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Stevanato Group Soars 14.92% in Pre-market on Strong Q4 Earnings Beat and Robust 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Stevanato Group Soars 14.92% in Pre-market on Strong Q4 Earnings Beat and Robust 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-04 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The pharmaceutical services company reported quarterly adjusted earnings of €0.18 per share, exceeding analyst estimates of €0.17. Revenue for the quarter rose to €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by a 31% jump in revenue from high-value solutions, which reached a record €171.4 million and represented 49% of total Q4 revenue.</p><p>For fiscal year 2026, Stevanato Group provided guidance that includes revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STVN","symbol_name":"Stevanato Group S.p.A.","start_time":0,"source_url":"","article_id":"1139133359","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139133359","pubTimestamp":1772630957,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.The pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STVN":"Stevanato Group S.p.A."},"translate_title":"股票追踪|Stevanato Group盘前飙升14.92%，第四季度盈利强劲，2026年指引稳健","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STVN":1},"content_text":"Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.The pharmaceutical services company reported quarterly adjusted earnings of €0.18 per share, exceeding analyst estimates of €0.17. Revenue for the quarter rose to €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by a 31% jump in revenue from high-value solutions, which reached a record €171.4 million and represented 49% of total Q4 revenue.For fiscal year 2026, Stevanato Group provided guidance that includes revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}